2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes
Netherlands Heart Journal · 2025 · Europe
Source and licence
- Authors
- Fabrice M A C Martens, Frank L J Visseren, Jan Westerink et al.
- Title
- 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes
- Journal
- Netherlands Heart Journal, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12274173
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
This is a review of another guideline (2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, ESC 2023). We do not reproduce that guideline's recommendations here – they belong to the original guideline.
Open the original publication →Full text on Europe PMC
Abstract
The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.
Contents of the original publication
The section headings of the original.
- Introduction
- Screening and cardiovascular risk assessment (Infobox 1)
- Screening for T2DM in patients with CVD
- Screening for CVD, heart failure and chronic kidney disease in patients with T2DM
- Evidence-based, personalised treatment strategies in patients with CVD and T2DM (Infobox 2)
- Preferred CVD risk-lowering agents in T2DM
- What is new and useful to know for cardiologists?
- Deviations from the ESC Guidelines for daily clinical practice in the Netherlands
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint